TGen, Genomic Health ID Potential Oxaliplatin Response Genes; Findings May Enhance Colon Cancer Test
January 19, 2011
TGen, Genomic Health ID Potential Oxaliplatin Response Genes; Findings May Enhance Colon Cancer Test
The study identified 27 genes that might impact colon cancer patients' response to oxaliplatin, a finding that could help Genomic Health add a treatment benefit indication to its Oncotype DX test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- QUASAR Study Shows Oncotype DX Gauges Colon Cancer Recurrence Risk, Doesn't Predict Treatment Benefit
November 9, 2011 / Pharmacogenomics Reporter - Genomic Health Accelerates Timeline for Prostate Cancer Test
January 10, 2011 / GenomeWeb Daily News - Deal with NewBridge Allows Genomic Health to Expand Oncotype DX into Africa, Middle East
August 13, 2012 / GenomeWeb Daily News - Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance
July 3, 2012 / Pharmacogenomics Reporter - MDx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 13, 2012 / Pharmacogenomics Reporter